Bempedoic acid 180 mg tablet
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Conditions
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Trial Timeline
Apr 1, 2025 → Oct 15, 2025
NCT ID
NCT06925100About Bempedoic acid 180 mg tablet
Bempedoic acid 180 mg tablet is a approved stage product being developed by Daiichi Sankyo for Primary Hypercholesterolemia or Mixed Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT06925100. Target conditions include Primary Hypercholesterolemia or Mixed Hyperlipidemia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06925100 | Approved | Completed |
Competing Products
20 competing products in Primary Hypercholesterolemia or Mixed Hyperlipidemia